Our valued sponsor

Sword and Shield

Novartis’ Multiple Sclerosis Pill Faces FDA Review (Update1)

guest

guest

Cyprus Company Formation
Dec 30, 2008
13,766
35
48
75
#1
Novartis AG’s drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.


More...
 
You must log in or register to reply here.

Forum Announcement

Latest Threads

Offshore Bank Accounts
The Kingdom Bank
Top Bottom
Back